CPT® Code 90587

1. Indications

The quadrivalent dengue vaccine is indicated for individuals who are at risk of contracting dengue fever, particularly in areas where the disease is endemic. The following conditions and circumstances warrant the administration of this vaccine:

• High Risk of Dengue Exposure Individuals living in or traveling to regions where dengue fever is prevalent are at increased risk of exposure to the virus.
• Previous Dengue Infection Individuals who have had a previous dengue infection may benefit from vaccination to help prevent future infections from different serotypes.
• Age Appropriateness The vaccine is typically recommended for individuals within the appropriate age range as specified by health authorities, ensuring that the target population receives the vaccine effectively.

2. Procedure

The administration of the quadrivalent dengue vaccine follows a structured three-dose schedule, which is critical for ensuring optimal immune response. The procedural steps are as follows:

• Step 1: Initial Dose The first dose of the vaccine is administered subcutaneously, typically at the initial visit. This dose serves as the foundation for the immune response, introducing the attenuated virus to the immune system.
• Step 2: Second Dose The second dose is given six months after the initial dose. This booster dose is essential for enhancing the immune response and ensuring that the body develops a robust defense against the dengue virus.
• Step 3: Third Dose The final dose is administered twelve months after the second dose. This third dose solidifies the immune memory, providing long-term protection against the four serotypes of the dengue virus.

3. Post-Procedure

After the administration of the quadrivalent dengue vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions. Common post-vaccination care includes advising patients about potential mild side effects, such as soreness at the injection site, low-grade fever, or fatigue. Patients should be informed about the importance of completing the full three-dose schedule to achieve maximum immunity. Additionally, individuals should be counseled on the continued need for protective measures against mosquito bites, as the vaccine does not provide immediate protection and does not eliminate the risk of dengue infection entirely.